Palleiko Benjamin L 4

What Happened Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals (KALV), had 15,625 restricted stock units (RSUs) convert to common shares on 2026-03-06. Following that vesting/settlement, he sold 6,693 shares in an open-market "sell-to-cover" transaction on 2026-03-09 for approximately $107,633 (reported weighted-average price shown as $16.08). The RSU conversion did not require cash payment by the insider.

Key Details

• Primary actions: RSU settlement (conversion/exercise) of 15,625 shares on 2026-03-06; open-market sale of 6,693 shares on 2026-03-09.
• Sale proceeds: $107,633 (reported price in table $16.08; filing notes weighted-average prices in the range $16.08–$16.4102).
• Reason for sale: sell-to-cover to satisfy tax withholding obligations in connection with RSU vesting (footnote F2); not a discretionary investment sale by the CEO.
• RSU terms: each RSU converts to one share for no consideration (F1); vesting schedule is 1/16th of total RSUs each quarterly anniversary beginning June 6, 2024 (F4).
• Shares owned after the transactions: not specified in the Form 4 filing.

Context

• This sequence is a routine RSU vesting and tax-withholding sale (common for employees/executives); the insider converted RSUs into shares and sold a portion immediately to cover taxes. The filing does not indicate a separate market-timed investment decision.